ArticleJournal of virology2000
Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 420 citations in OpenAlex.
- Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.PloS one · 2017Trial
- Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection.PLoS pathogens · 2016Trial
- Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.Nature communications · 2013Trial
- Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.The Journal of infectious diseases · 2012Trial
- BATF3 regulates differentiation of CD8Life science alliance · 2026Article
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study.PLoS pathogens · 2025Article
- Study of Peripheral Blood T-Lymphocytes and Their Subpopulations in COVID-19 Patients.Biochemistry research international · 2025Article
- The Wide Spectrum of Presentations of Cytomegalovirus Infection in Immunocompetent Hosts: An Exhaustive Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Exploring the relationship between HCMV serostatus and outcomes in COVID-19 sepsis.Frontiers in immunology · 2024Observational
- Expansion of effector memory Vδ2Frontiers in immunology · 2024Article
- Immune-checkpoint expression in antigen-presenting cells (APCs) of cytomegaloviruses infection after transplantation: as a diagnostic biomarker.Archives of microbiology · 2023Review
- Overall avidity declines in TCR repertoires during latent CMV but not EBV infection.Frontiers in immunology · 2023Article
- Refractory Cytomegalovirus Colitis in Common Variable Immunodeficiency Requiring Total Colectomy.Case reports in gastrointestinal medicine · 2023Article
- Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells.Oncoimmunology · 2023Article
- Cellular Senescence in Immunity against Infections.International journal of molecular sciences · 2022Review
- Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self.Circulation research · 2022Article
- Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.Journal of clinical immunology · 2022Article
- Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases.International journal of molecular sciences · 2021Review
- Immunotherapy with adoptive cytomegalovirus-specific T cells transfer: Summarizing latest gene engineering techniques.Health science reports · 2021Review
97 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) infection is largely asymptomatic in the immunocompetent host, but remains a major cause of morbidity in immunosuppressed individuals. Using the recently described technique of staining antigen-specific CD8(+) T cells with peptide-HLA tetrameric complexes, we have demonstrated high levels of antigen-specific cells specific for HCMV peptides and show that this may exceed 4% of CD8(+) T cells in immunocompetent donors. Moreover, by staining with tetramers in combination with antibodies to cell surface markers and intracellular cytokines, we demonstrate functional heterogeneity of HCMV-specific populations. A substantial proportion of these are effector cytotoxic T lymphocytes, as demonstrated by their ability to lyse peptide-pulsed targets in "fresh" killing assays. These data suggest that the immune response to HCMV is periodically boosted by a low level of HCMV replication and that sustained immunological surveillance contributes to the maintenance of host-pathogen homeostasis. These observations should improve our understanding of the immunobiology of persistent viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.